MétaCan
Menu
Back to cohort
Record W2034524595 · doi:10.1002/ibd.20069

Linear Growth Improves during Infliximab Therapy in Children with Chronically Active Severe Crohnʼs Disease

2006· article· en· W2034524595 on OpenAlexaff
Thomas D. Walters, Ashley Gilman, Anne M. Griffiths

Bibliographic record

VenueInflammatory Bowel Diseases · 2006
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsSickKids FoundationHospital for Sick ChildrenUniversity of Toronto
Fundersnot available
KeywordsInfliximabMedicineRegimenRefractory (planetary science)Internal medicineCorticosteroidGastroenterologyDiseaseSurgeryPediatrics

Abstract

fetched live from OpenAlex

BACKGROUND: The efficacy of infliximab as maintenance therapy in patients with otherwise chronically active Crohn's disease (CD) is well established. Data concerning the linear growth response are sparse and can only be accrued in children. METHODS: From September 2000 to February 2004, 32 children and adolescents (63% males; mean age 13.4 years, range 4.7-17.3) with chronically active CD despite immunomodulatory and prior corticosteroid therapy commenced infliximab therapy. Growth parameters standardized for age, gender, and pubertal development prior to and following infliximab therapy were compared. RESULTS: In all, 28 of 32 patients tolerated and responded to the induction regimen and 27 responders continued to receive infliximab via regularly scheduled infusions (n = 22) or episodically (n = 5) for a median of 26 months. Mean standard deviation score (SDS) for height at time of initiation of infliximab therapy was -1.15 +/- 1.2 and had declined despite the use of other therapies from -0.44 +/- 1.1 at initial diagnosis. Increases in height velocity and stature during infliximab therapy were limited by pubertal stage: Tanner I-III: DeltaSDS for height velocity +3.94, for height +0.50, P < 0.001; Tanner IV, V: DeltaSDS for height velocity +0.22, for height 0.02, P = NS. CONCLUSIONS: Height velocity improves and height centile increases during infliximab therapy provided patients are treated prior to or in early puberty. These data support the use of infliximab in young patients with otherwise refractory disease, and suggest that ultimate height in this subset of children with severe CD may be less compromised than with previous therapies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.003
GPT teacher head0.202
Teacher spread0.199 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations142
Published2006
Admission routes1
Has abstractyes

Explore more

Same venueInflammatory Bowel DiseasesSame topicInflammatory Bowel DiseaseFrench-language works237,207